RxDoctor Payments DataLook up a doctor →

Paramvir Sidhu, MD

Rheumatology · Goodyear, AZNPI 1124220116

Payments from drug & device makers

$811,914in general payments, 2019–2025

Across 352 payments — averaging $2306.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$738K
  • AbbVie$26K
  • GSK$20K
  • UCB SA$13K
  • Novartis$4K
  • Aurinia Pharma U.S., Inc.$4K
  • plus $6K from 15 others

What the payments were for

  • Consulting fees$10,03546%
  • Speaking & faculty fees$3,39016%
  • Travel & lodging$2281%
  • Food & beverage$7,86736%
  • Education$810%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$811,914 in reported general payments places this provider in the 80th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona

Medicare billing

Part B allowed, 2024
$69,753
Medicare patients
366
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib52$363,583
Cosentyx Sensoready PenSecukinumab18$231,100
Enbrel SureclickEtanercept29$223,967
Taltz AutoinjectorIxekizumab12$207,645
Humira(Cf) PenAdalimumab20$186,917
Actemra ActpenTocilizumab32$155,574
KevzaraSarilumab34$148,092
Cosentyx Sensoready (2 Pens)Secukinumab13$111,703
Enbrel MiniEtanercept11$95,352
Orencia ClickjectAbatacept13$73,013
OtezlaApremilast12$65,343
TymlosAbaloparatide11$29,309
ProliaDenosumab15$25,202
Mycophenolate Mofetil22$7,312
MethotrexateMethotrexate Sodium151$4,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$26,458$363,58352 claims
SanofiKevzara$315$148,09234 claims
AmgenOtezla, Prolia$737,957$90,54627 claims
Radius Health, Inc.Tymlos$19$29,30911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 rheumatology providers in Arizona.

Other rheumatology in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →